Aus dem Newsletter von Multidisciplinary Association for Psychedelic Studies (MAPS):
In just one week— on November 29, 2016 — we’ll meet with the U.S. Food and Drug Administration (FDA) to review the promising data from our completed Phase 2 studies of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), and to plan the design of our upcoming Phase 3 trials.
Sie brauchen aber noch ein paar Euro für den Stoff – Spende jetzt!
Die aktuellen Zwischenergebnisse sehen gut aus:
Results in 107 international subjects have been extremely promising. Of 65 subjects interviewed one year after treatment, 66% no longer had PTSD.
- Mehr zum Thema: MDMA-Assisted Psychotherapy